Connect with us
Editorial & Advertiser disclosureOur website provides you with information, news, press releases, Opinion and advertorials on various financial products and services. This is not to be considered as financial advice and should be considered only for information purposes. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third party websites, affiliate sales networks, and may link to our advertising partners websites. Though we are tied up with various advertising and affiliate networks, this does not affect our analysis or opinion. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you, or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish sponsored articles or links, you may consider all articles or links hosted on our site as a partner endorsed link.

News

Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics

gbafNews28

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., Astellas) and Audentes Therapeutics, Inc. (NASDAQ: BOLD, Chairman and CEO: Matthew R. Patterson, Audentes), today announced that they have entered into a definitive agreement for Astellas to acquire Audentes at a price of US$60.00 per share in cash, representing a total equity value of approximately US$3 billion.

Recent scientific and technological advances in genetic medicine have advanced the potential to deliver unprecedented and sustained value to patients, and even to curing diseases with a single intervention, said Kenji Yasukawa, President and CEO, Astellas. Audentes has developed a robust pipeline of promising product candidates which are complementary to our existing pipeline, including its lead program AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM). By joining together with Audentes talented team, we are establishing a leading position in the field of gene therapy with the goal of addressing the unmet needs of patients living with serious, rare diseases.

We are very pleased to enter into this merger agreement with Astellas, stated Matthew R. Patterson, Chairman and Chief Executive Officer of Audentes. With its focus on innovative science and a global network of research, development and commercialization resources, we believe that operating as part of the Astellas organization optimally positions us to advance our pipeline programs and serve our patients.

The acquisition of Audentes represents a key step in the expansion of the Astellas Focus Area approach, under which Astellas strives to create innovative medicines for diseases with high unmet medical needs by identifying unique combinations of biology and therapeutic modality/technology based on emerging science. In addition to the four Primary Focus Areas in which Astellas currently prioritizes its investment, with the acquisition of Audentes, the company is adding a fifth Primary Focus Area in Genetic Regulation, under which gene therapy will be a key driver of the companys future growth.

Strategic Significance of the Acquisition

  • Accesses the near-term growth opportunity of AT132, in development for the treatment of XLMTM, a serious, life-threatening, rare neuromuscular disease that is characterized by extreme muscle weakness, respiratory failure and early death.
  • Accelerates the development of a robust pipeline of potentially best-in-class genetic medicines for rare neuromuscular diseases, by combining Astellas scientific capabilities and global resources with Audentes AAV gene therapy technology platform, in-house large-scale cGMP manufacturing and neuromuscular development expertise.
  • Creates the opportunity for additional gene therapy partnerships and pipeline expansion through leveraging Audentes manufacturing capabilities and its valued relationships with patient groups, academic collaborators and scientific advisors.

Transaction Details

Under the agreement, which has been unanimously approved by the boards of directors of both Astellas and Audentes, Astellas will acquire Audentes through Asilomar Acquisition Corp., a wholly-owned subsidiary of Astellas US Holding, Inc. (Asilomar). Asilomar will commence a tender offer for all outstanding shares of common stock of Audentes, for a price of US$60.00 per share in cash (the Tender Offer). Promptly upon successful completion of the Tender Offer, Asilomar will be merged into Audentes, and any remaining shares of common stock of Audentes will be canceled and converted into the right to receive the same US$60.00 per share price. The board of directors of Audentes has resolved to recommend that Audentes stockholders tender their shares to Astellas.

Financial Details and Closing Conditions

Consummation of the transaction is subject to customary closing conditions, including US antitrust clearance and the tender of a majority of Audentes outstanding shares of common stock. The offer price represents a premium of 110% to Audentes closing share price of US$28.61 on December 2, 2019. The all-cash transaction is valued at approximately US$3 billion including the purchase of all common shares, options, restricted stock units and other securities. The Tender Offer period is expected to commence in the next few weeks and to expire 20 business days after its commencement, unless otherwise extended. If the Tender Offer conditions are not satisfied, Astellas may be required to extend the Tender Offer under certain circumstances.

Astellas is still reviewing the impact of a consummation of the transaction on its financial results for the fiscal year ending March 31, 2020.

Morgan Stanley & Co. LLC, acting through its affiliate Mitsubishi UFJ Morgan Stanley Securities Co., Ltd., is acting as exclusive financial advisor to Astellas and Covington & Burling LLP is acting as its legal counsel.

Centerview Partners LLC is acting as exclusive financial advisor to Audentes and Fenwick & West LLP is acting as its legal counsel.

About Astellas Pharma Inc.

Astellas Pharma Inc., based in Tokyo, Japan, is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information, please visit Astellas website at https://www.astellas.com/en.

About Audentes Therapeutics, Inc.

Audentes Therapeutics (Nasdaq: BOLD) is a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases. Audentes is leveraging AAV gene therapy technology platform and proprietary manufacturing expertise to develop programs across three modalities: gene replacement, vectorized exon skipping, and vectorized RNA knockdown. Its product candidates are showing promising therapeutic profiles in clinical and preclinical studies across a range of neuromuscular diseases. Audentes is a focused, experienced and passionate team driven by the goal of improving the lives of patients. For more information regarding Audentes, please visit www.audentestx.com.

Cautionary Notice Regarding Forward-Looking Statements

This document contains forward-looking statements relating to the acquisition of Audentes by Astellas. Such forward-looking statements include, but are not limited to, the ability of Audentes and Astellas to complete the transactions contemplated by the merger agreement, including the parties ability to satisfy the conditions to the consummation of the offer contemplated thereby and the other conditions set forth in the merger agreement, statements about the expected timetable for completing the transaction, Astellas and Audentes beliefs and expectations and statements about the benefits sought to be achieved in Astellas proposed acquisition of Audentes, the potential effects of the acquisition on both Astellas and Audentes, the possibility of any termination of the merger agreement, as well as the expected benefits and success of Audentes product candidates, the timing and nature of regulatory filings for Audentes product candidates, the timing of Audentes presentation of non-clinical data and the timing and nature of Audentes preclinical studies, clinical trials and manufacturing activities. In some cases, forward-looking statements may be identified by terminology such as believe, may, will, should, predict, goal, strategy, potentially, estimate, continue, anticipate, intend, could, would, project, plan, expect, seek and similar expressions and variations thereof. These words are intended to identify forward-looking statements. Astellas and Audentes have based these forward-looking statements on current expectations and projections about future events and trends that they believe may affect the financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs of Astellas and Audentes, but there can be no guarantee that such expectations and projections will prove accurate in the future.

All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Actual results may differ materially from current expectations because of risks associated with uncertainties as to the timing of the offer and the subsequent merger; uncertainties as to how many of Audentes stockholders will tender their shares in the offer; the risk that competing offers or acquisition proposals will be made; the possibility that various conditions to the consummation of the merger and the offer contemplated thereby may not be satisfied or waived; the effects of disruption from the transactions contemplated by the merger agreement on Audentes business and the fact that the announcement and pendency of the transactions may make it more difficult to establish or maintain relationships with employees, suppliers and other business partners; and the risk that stockholder litigation in connection with the offer or the merger may result in significant costs of defense, indemnification and liability. Moreover, Astellas and Audentes operate in very competitive and rapidly changing environments, and new risks emerge from time to time. Although Astellas and Audentes believe that the expectations reflected in such forward-looking statements are reasonable, they cannot guarantee future events, results, actions, levels of activity, performance or achievements, business and market conditions, the timing and results of biotechnology development and potential regulatory approval and whether the conditions to the closing of the proposed transaction are satisfied on the expected timetable or at all. Forward-looking statements are also subject to risks and uncertainties pertaining to the business of Audentes, including those set forth in the Risk Factors and Managements Discussion and Analysis of Financial Condition and Results of Operations sections of Audentes Annual Report on Form 10-K for the year ended December 31, 2018 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, which are on file with the SEC and available on the SECs website at www.sec.gov. In addition to the risks described above and in Audentes other filings with the SEC, other unknown or unpredictable factors could also affect Audentes results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information contained in this document is provided only as of the date hereof, and no party undertakes any obligation to revise or update any forward-looking statements to reflect events or circumstances after the date hereof, except as required by law.

Important Additional Information

The tender offer for the outstanding shares of common stock of Audentes has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell shares of Audentes common stock, nor is it a substitute for the tender offer materials that Astellas and its acquisition subsidiary will file with the SEC upon commencement of the tender offer. At the time the tender offer is commenced, Astellas will file a tender offer statement on Schedule TO with the SEC, and thereafter Audentes will file a solicitation/recommendation statement on Schedule 14D-9 with respect to the offer. THE TENDER OFFER STATEMENT (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND OTHER OFFER DOCUMENTS) AND THE SOLICITATION / RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY AND CONSIDERED BY AUDENTES STOCKHOLDERS BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. Both the tender offer statement and the solicitation/recommendation statement will be mailed to Audentes stockholders free of charge. A free copy of the tender offer statement and the solicitation/recommendation statement will also be made available to all stockholders of Audentes by contacting Audentes at [email protected] or by phone at (415) 818-1033. In addition, the tender offer statement, the related letter of transmittal and certain other tender offer documents and the solicitation/recommendation statement (and all other documents filed with the SEC) will be available at no charge on the SECs website: www.sec.gov, upon filing with the SEC. In addition to these documents, Audentes files annual, quarterly and current reports and other information with the SEC. These filings with the SEC are also available to the public for free at the SECs website at www.sec.gov. In addition, the solicitation/recommendation statement and the other documents filed by the Audentes with the SEC are available to all stockholders of Audentes free of charge at https://investors.audentestx.com/sec-filings.

AUDENTES STOCKHOLDERS ARE ADVISED TO READ THE SCHEDULE TO AND THE SCHEDULE 14D-9 CAREFULLY, AS EACH MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME, AND ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC WHEN THEY BECOME AVAILABLE BEFORE THEY MAKE ANY DECISION WITH RESPECT TO THE TENDER OFFER, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO, AS WELL AS IMPORTANT INFORMATION THAT HOLDERS OF SHARES OF AUDENTES COMMON STOCK SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES.

Astellas Pharma Inc.

Corporate Communications

TEL: +81-3-3244-3201 FAX: +81-3-5201-7473

Audentes Therapeutics, Inc.

Investors Contact:

Andrew Chang

TEL: +1-415-818-1033 Email: [email protected]

Media Contact:

Sarah Spencer

TEL: +1-415-957-2020 Email: [email protected]

News

The LYCRA Company to Showcase Latest Technologies at Intertextile Shanghai

gbafNews28

The LYCRA Company, a global leader in developing innovative fiber and technology solutions for the apparel industry, will exhibit its latest products designed to meet consumer needs at Intertextile Shanghai, which takes place on September 23-25. Themed RENEW, REDEFINE, REINFORCE, the presence at the show will allow visitors to learn about the new LYCRA Anti-Slip fiber technology. Other well-received technologies such as LYCRA FitSense„¢ technology, LYCRA MyFit„¢ fiber and COOLMAX freshFX technology will also be showcased.

Every industry is facing unprecedented challenges this year and the apparel industry is no exception, said Julien Born, President, Apparel, The LYCRA Company. We have been pleased to see that, despite market uncertainties, there is still a strong appetite for innovation as brands look to keep an edge and offer better value to consumers. Innovation has always been in The LYCRA Companys DNA, which we believe is key to address the increasing demands for functional and sustainable apparels globally.

Asia is set to be the key driver for The LYCRA Companys global growth, said Steve Stewart, Apparel Vice President, Asia, The LYCRA Company. As such, we will continue our innovation journey by launching new technologies, such as the ones we are showcasing at Intertextile. Only by working closely with our partners and customers can we empower our customers to gain a winning edge and fully capture the opportunities offered by a new global economy.

A New Innovation Frontier

LYCRA Anti-Slip fiber is an exceptional denim seam slippage solution for applications in single core spandex fabrics that require durable stretch and good recovery power. Designed to help prevent seam slippage and improve garment quality and yield, this patent pending fiber helps maintain garment appearance wash after wash and wear after wear. It is a versatile fiber that makes possible for a multitude of fabric developments and constructions, including open structures and use of polyester/viscose blends, and cotton blends achieving a soft touch and authentic appearance.

By using LYCRA Anti-Slip fiber in the core of LYCRA dualFX technology yarn, the anti-slippage performance will be further enhanced. It is based on several patented technologies from The LYCRA Company related to both dual core and bi-component yarns. By combining LYCRA Anti-Slip fiber and LYCRA T400 fiber together in one fabric, the key benefit is the high stretch of LYCRA fiber with exceptional slippage solution plus the excellent recovery power of LYCRA T400 fiber. This means that consumers can have super stretch jeans that last longer and keep its fit and shape. Consumers will look good all day, every day.

The Power of The Science of Fit„¢

LYCRA FitSense„¢ technology is a patented, water-based dispersion that features the same molecules as LYCRA fiber, but in liquid form. This revolutionary innovation is screen printed onto fabric containing LYCRA fiber to provide lightweight, targeted support across a range of garment types. This solution also helps streamline garment manufacturing through the potential elimination of double-layers and extra seams and offers unlimited design possibilities for brands and retailers.

LYCRA MyFit„¢ fiber is a patent-pending, fiber technology engineered with a polymer designed to deliver improved comfort and fit. The result is greater shape tolerance and a customized fit experience for a differing range of body shapes. Ultimately, it gives brands and retailers the potential to higher customer satisfaction, minimize returns, reduce SKUs and costs by undercutting patterns.

LYCRA FitSense„¢ technology and LYCRA MyFit„¢ fiber have been well received by both international and domestic brands since their launch to the market. The two innovations now find wide applications in various apparel categories from underwear and activewear to seamless garments as well as swimwear.

Anti-Odor Fiber for 24/7 Freshness

COOLMAX freshFXtechnology actively suppresses the growth of bacteria which are the root cause of body odor and related smells and therefore is perfectly adapted for applications such as sportswear and underwear to offer freshness. The active ingredient in COOLMAX freshFX qualifying fibers is a durable, non-migratory silver-based antimicrobial additive. The active ingredient is spun directly into the yarn, rather than being topically applied, and an inorganic cage matrix protects it. Therefore, it can be expected to remain effective for the life of the garment even after repeated laundering.

The Legwear Stars

LYCRA FUSION„¢ technology helps make hosiery resistant to runs, which can improve the wear life of the garment. LYCRA SOFT COMFORT technology imparts a soft and comfortable stretch to sock tops and knee-high tops. The technology is based on soft-stretch LYCRA fibers that combine high elongation with low hysteresis. This makes garments easy to don but with a firm and secure fit.

The beginning of 2020 may have taken us by surprise, yet I am excited to see the speedy recovery across Asia-Pacific, particularly in China, said Jack Yang, R&D Director, The LYCRA Company. Technology and innovation are now the oxygen of every business. With our legacy and profound understanding of the apparel and textile industry, we are excited to work with our partners in China to bring more consumer-centric innovation to the world.

To bring to life The LYCRA Companys newest innovations at Intertextile, the technologies will be introduced via multimedia channels such as LED videos and augmented reality technology. Sample fabrics and garments experience will be available at the booth for further engagement. There is also a bottle calculator for visitors to understand how many plastic bottles are being put into use again in a garment by providing fabric weight and EcoMade fiber content. To learn more about the latest developments of The LYCRA Company, visit Intertextile booth H4.1-E56.

In addition to the physical booth, The LYCRA Company also offers a virtual tour and daily highlights on connect.lycra.com/intertextile2020. Check out the site to learn more about our technologies and to hear our customers stories.

For show information, visit Intertextile.com.

About The LYCRA Company

The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries, as well as specialty chemicals used in the spandex and polyurethane value chains. Headquartered in Wilmington, Delaware, The LYCRA Company is recognized worldwide for its innovative products, technical expertise, and unmatched marketing support. The LYCRA Company owns leading consumer and trade brands: LYCRA, LYCRA HyFit, LYCRA T400, L by LYCRA, COOLMAX, THERMOLITE, ELASPAN, SUPPLEX and TACTEL. While The LYCRA Companys name is new, its legacy stretches back to 1958 with the invention of the original spandex yarn, LYCRA fiber. Today, The LYCRA Company is focused on adding value to its customers products by developing unique innovations designed to meet the consumers need for comfort and lasting performance. For more information, visit www.thelycracompany.com.

LYCRA FitSense„¢, LYCRA MyFit„¢, LYCRA dualFX and COOLMAX freshFX are all trademarks of The LYCRA Company.

Kristin Altimari

[email protected]

Continue Reading

News

Catalyst Regeneration Market 2020 – 2024: Post-Pandemic Industry Planning Structure | Technavio

gbafNews28

The catalyst regeneration market is expected to grow by USD 1.18 billion during 2020-2024, according to Technavio. The report offers a detailed analysis of the impact of COVID-19 pandemic on the catalyst regeneration market in optimistic, probable, and pessimistic forecast scenarios.

The catalyst regeneration market will witness neutral and at par impact during the forecast period owing to the widespread growth of the COVID-19 pandemic. As per Technavios pandemic-focused market research, market growth is likely to Increase as compared to 2019.

Enterprises will go through Respond, Recover and Renew phases. Download free report sample

As the COVID-19 pandemic continues to spread, organizations across the globe are gradually flattening their recessionary curve by leveraging technology. Many businesses will go through respond, recover and renew phases. Building business resilience and enabling agility will aid organizations to move forward in their journey out of the COVID-19 crisis and towards the Next Normal.

This post-pandemic business planning research will aid clients to:

  • Adjust their strategic planning to move ahead once business stability kicks in.
  • Build Resilience by making effective resource and investment choices for individual business units, products and service lines.
  • Conceptualize scenario-based planning to mitigate future crisis situations.

Download the Post-Pandemic Business Planning Structure. Click here

Key Considerations for Market Forecast:

  • Impact of lockdowns, supply chain disruptions, demand destruction, and change in customer behavior
  • Optimistic, probable, and pessimistic scenarios for all markets as the impact of pandemic unfolds
  • Pre- as well as post-COVID-19 market estimates
  • Quarterly impact analysis and updates on market estimates

Gain instant access to 17,000+ market research reports by using

Technavio’s SUBSCRIPTION platform

Major Three Catalyst Regeneration Market Participants:

Nippon Ketjen Co. Ltd.

Nippon Ketjen Co. Ltd. operates its business under products & services segments. The company offers a wide range of catalyst regeneration products and services such as hydroprocessing catalysts, off-site regeneration/rejuvination service, collaborative work. The products include guard grades, hydrotreatment of naphtha, kerosene, and diesel, hydrotreatment of VGO, and hydrotreatment of residue.

Porocel

Porocel operates its business under products and catalyst services segments. The company offers a wide range of catalyst regeneration products and services such as activated alumina, catalyst substrates and powders, activated bauxite, rejuvenation catalyst services, presulfurization, FCC catalyst services, and others.

STEAG GmbH

STEAG GmbH has business operations under services segments. The company offers a wide range of catalyst regeneration services such as NOx emission control, combustion optimization, SO emissions, mercury emissions, and others.

If you purchase a report that is updated in the next 60 days, we will send you the new edition and data extract FREE! Get report snapshot here to get detailed market share analysis of market participants during COVID-19 lockdown: https://www.technavio.com/report/ catalyst regeneration market-industry-analysis

Catalyst Regeneration Market 2020-2024: Segmentation

Catalyst Regeneration is segmented as below:

  • Type
    • Off-site
    • On-site
  • Geography
    • North America
    • Europe
    • APAC
    • MEA
    • South America

The catalyst regeneration market is driven by the increasing practice of catalyst shifting. In addition, other factors such as the adoption of process optimization by refineries to reduce costs are expected to trigger catalyst regeneration market toward witnessing a CAGR of over 4% during the forecast period.

Get more insights about the global trends impacting the future of catalyst regeneration market, Request Free Sample @ https://www.technavio.com/talk-to-us?report=IRTNTR45153

Market Drivers

Market Challenges

Market Trends

Vendor Landscape

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Competitive scenario

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: [email protected]

Website: www.technavio.com/

Continue Reading

News

Visible Supply Chain Management Executive Emma Leonard Named 2020 Women in Supply Chain Award Winner by Supply & Demand Chain Executive

gbafNews28

Acknowledging her accomplishments, leadership and best-practice example for women leaders in supply chain, Emma Leonard, executive vice president at Visible Supply Chain Management (Visible), has been recognized as a 2020 Women in Supply Chain award winner by Supply & Demand Chain Executive.

The Women in Supply Chain award honors female supply chain leaders and executives whose accomplishments, mentorship and examples set a foundation for women in all levels of a companys supply chain network.

Emmas efforts have played a major role in Visibles ability to provide a ‘best in class’ customer experience and has added tremendous value to our clients, said Casey Adams, president of Visible. She has exhibited strong leadership abilities by building and managing a cross-functional team of transportation professionals, analysts and managers. This award is well deserved.

In an industry in which female executives are relatively uncommon, the excellence Emma displays each day is an unassailable argument for the increased need for women leadership in supply chain. She is a shining example for all mentoring her peers by organizing and facilitating local networking events. In addition, Emma is actively involved in AWESOME (Achieving Womens Excellence in Supply Chain Operations, Management and Education).

Because of women like Emma, 17% of chief supply chain officers are now women a 6% increase compared to 2019, according to Gartners 2020 Women in Supply Chain Survey.

Supply & Demand Chain Executive celebrates its 20th anniversary by introducing the new award designed specifically for women leaders in the supply chain industry.

We received over 200 entries for the new Women in Supply Chain award, entries that were submitted from a combination of men and women. This proves that our industry needed an award like this, said Marina Mayer, editor-in-chief of Supply & Demand Chain Executive and Food Logistics. Congratulations to these top female leaders. I look forward to seeing how they grow the supply chain industry.

Check out Supply & Demand Chain Executives website at www.sdcexec.com for the full list of the 2020 Women in Supply Chain winners. The 2020 Women in Supply Chain award will appear in SDCEs September issue.

About Visible Supply Chain Management (Visible)

Since 1992, Visible Supply Chain Management has provided customized solutions for B2B and B2C organizations. With comprehensive services in e-commerce, direct sales, direct response and omnichannel, Visible can design effective strategies for clients that include transportation, logistics, brokerage, fulfillment and even custom packaging solutions.

About Supply & Demand Chain Executive

Supply & Demand Chain Executive is the executive’s user manual for successful supply and demand chain transformation, utilizing hard-hitting analysis, viewpoints and unbiased case studies to steer executives and supply management professionals through the complicated, yet critical, world of supply and demand chain enablement to gain competitive advantage. Go to www.SDCExec.com.

Shannon Michael, SnappConner PR

801.205.6714

[email protected]

Continue Reading
gbafNews28 gbafNews28
News2 hours ago

The LYCRA Company to Showcase Latest Technologies at Intertextile Shanghai

The LYCRA Company, a global leader in developing innovative fiber and technology solutions for the apparel industry, will exhibit its...

gbafNews28 gbafNews28
News2 hours ago

Visible Supply Chain Management Executive Emma Leonard Named 2020 Women in Supply Chain Award Winner by Supply & Demand Chain Executive

Acknowledging her accomplishments, leadership and best-practice example for women leaders in supply chain, Emma Leonard, executive vice president at Visible...

gbafNews28 gbafNews28
News2 hours ago

Catalyst Regeneration Market 2020 – 2024: Post-Pandemic Industry Planning Structure | Technavio

The catalyst regeneration market is expected to grow by USD 1.18 billion during 2020-2024, according to Technavio. The report offers...

gbafNews28 gbafNews28
News2 hours ago

Sitetracker Announces Unprecedented AI Capabilities to Fuel Data-Driven Decision Making and Revenue Growth for Its Customers

Sitetracker, the global standard for managing high-volume projects for infrastructure owners and operators like Verizon, Vodafone, SAC Wireless, and ChargePoint,...

gbafNews28 gbafNews28
News2 hours ago

Balfour Beatty, as Part of LINXS Joint Venture, Completes Major Milestones on the LAX Automated People Mover Project

Balfour Beatty, as part of the LAX Integrated Express Solutions (LINXS Constructors) joint venture team, completed an important milestone in...

gbafNews28 gbafNews28
News2 hours ago

Optomec Customer Carnegie Mellon Develops 10-Second COVID Test

Researchers at Carnegie Mellon University (CMU) have developed a low-cost sensor that can identify COVID-19 antibodies in approximately 10 seconds....

gbafNews28 gbafNews28
News2 hours ago

AM Best Affirms Credit Ratings of Stewart Title Group Members

AM Best has affirmed the Financial Strength Rating (FSR) of A- (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR)...

gbafNews28 gbafNews28
News2 hours ago

Smart Eats Digital Series Teaches How to Not Get Fooled at the Supermarket, Launches September 23

Chef Monti Carlo, a notable culinary personality on Food Network and Cooking Channel, launches Smart Eats, a new digital show...

gbafNews28 gbafNews28
News2 hours ago

Limbach Holdings to Host Webinar on Thursday, October 1, 2020

Limbach Holdings, Inc. (NASDAQ: LMB) (Limbach or the Company) today announced that management will host a webinar event at 2...

gbafNews28 gbafNews28
News2 hours ago

12 Northern Illinois Arts Organizations Awarded Grants from ComEd, League of Chicago Theatres

As the COVID-19 continues to challenge the ways art is performed and experienced, ComEd and the League of Chicago Theatres...